<DOC>
	<DOCNO>NCT00016159</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy monoclonal antibody treat patient acute promyelocytic leukemia .</brief_summary>
	<brief_title>Chemotherapy Plus Monoclonal Antibody Treating Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine disease-free overall survival patient acute promyelocytic leukemia clinical complete remission follow tretinoin-based induction therapy treat monoclonal antibody HuG1-M195 , arsenic trioxide , idarubicin , tretinoin . - Determine rate molecular complete remission patient treat regimen . - Determine toxicity regimen patient population . - Determine number length hospitalization patient treat regimen . OUTLINE : Patients receive monoclonal antibody HuG1-M195 ( MOAB HuM195 ) IV 40-60 minute twice weekly 3 week . Approximately 2-4 week completion MOAB HuM195 , patient receive arsenic trioxide IV 1-4 hour daily total 25 day 5 day dos . Beginning approximately 4-6 week completion arsenic trioxide , patient receive idarubicin IV daily day 1-3 1-4 filgrastim ( G-CSF ) subcutaneously daily begin day 5 6 continue blood count recover . Treatment repeat every 4 week patient remain RT-PCR positive newly convert RT-PCR negative ( molecular complete remission ) follow prior course idarubicin maximum 3 course . Patients remain RT-PCR positive follow course 3 idarubicin receive treatment study . Beginning 3 month completion idarubicin , patient molecular complete remission receive oral tretinoin daily 14 day . Treatment repeat every 3 month total 6 course absence disease progression unacceptable toxicity . Patients follow monthly . PROJECTED ACCRUAL : Approximately 35 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute promyelocytic leukemia positive RTPCR assay PML/RARalfa rearrangement ( 15 ; 17 ) karyotype Achieved clinical complete remission within past 12 month Prior induction therapy must contain tretinoin No acute myeloid leukemia diagnosis PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 mg/dL Transaminases great 3 time upper limit normal Renal : Creatinine le 2 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : Ejection fraction normal great 50 % echocardiogram MUGA Other : No concurrent active malignancy No serious lifethreatening condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 1 week since prior retinoids Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior postremission therapy form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>